Krystal Biotech (KRYS) Profit After Tax (2016 - 2026)

Krystal Biotech has reported Profit After Tax for 11 years, with the latest figure at $54.8 million in Q2 2026.

• Profit After Tax for Q2 2026 came in at $54.8 million, up 40.07% year-over-year; the trailing twelve-month figure through Jun 2026 was $241.5 million (up 62.34% YoY), and the FY2025 annual result was $206.2 million, up 131.22% from the prior year.
• Profit After Tax fell to $54.8 million in Q2 2026, from $55.9 million in the prior quarter.
• Over five years, Profit After Tax peaked at $80.7 million in Q3 2023 and troughed at -$50.0 million in Q1 2022.
• A 5-year average of $15.5 million and a median of $22.4 million in 2024 frame the typical range for Profit After Tax.
• The widest annual swing landed in 2022, when Profit After Tax sank 215.99%; it then soared 3734.01% in 2025.
• A 5-year view of Profit After Tax shows it stood at -$31.3 million in 2022, then jumped by 131.02% to $9.7 million in 2023, then soared by 359.28% to $44.6 million in 2024, then climbed by 15.31% to $51.4 million in 2025, then rose by 6.48% to $54.8 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were $54.8 million in Q2 2026, $55.9 million in Q1 2026, and $51.4 million in Q4 2025.